森松國際(02155.HK)生物製藥高端裝備製造基地項目計劃落户常熟經濟技術開發區
格隆匯8月20日丨森松國際(02155.HK)宣佈,公司已於2021年7月29日與常熟經濟技術開發區管理委員會,其為受常熟市人民政府委託,負責對常熟經濟技術開發區進行開發建設、運營和管理的政府機構,簽署投資協議書,計劃將公司的生物製藥高端裝備製造基地項目落户常熟經濟技術開發區。
常熟經濟技術開發區坐落於毗鄰我們南通生產基地的蘇州地區,該地區被譽為中國藥谷。項目計劃用地逾200,000平方米,常熟經濟技術開發區管理委員會計劃將分兩期以土地使用權出讓的方式供集團使用。其中,一期項目用地約130,000平方米,總投資額約為美元1.8億元,預計資金來源包括公司全球發售募集資金、集團營運所得及銀行貸款等,具體情況將在項目計劃落實時確定。此外,二期項目是否開始亦會視情況而定。
公司計劃通過這一項目,在中國華東地區成立一家新的附屬公司,主要從事生物製藥、日化、電子化學品領域高端智能裝備和專業精密成套設備的製造。憑藉本集團在生物製藥領域的先進工藝、技術和強大研發能力,公司將進一步整合競爭優勢,為全球客户帶來更優質的數字化和智能化生物製藥等工廠解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.